Bidisomide (SC-40230) is an investigational pharmaceutical compound primarily studied for its role as an antiarrhythmic agent in the treatment of cardiac arrhythmias. It functions mainly as a class I antiarrhythmic by blocking sodium channels in cardiac cells, which helps reduce abnormal electrical signaling and stabilize heart rhythms. Additionally, it exhibits some class III-like properties by prolonging the action potential duration and refractory period, making it useful for conditions such as atrial fibrillation and ventricular tachycardia. Research continues to evaluate its efficacy, safety, and potential in patients unresponsive to standard therapies, though it remains in clinical development without widespread approval.